🧠 Targeting glutamate uptake pathways
By restoring glutamate homeostasis in a reward-relevant brain region, MC-100093 highlights a target-focused, mechanism-driven strategy for AUD pharmacotherapy.
👉 Read more on: doi.org/10.1093/ijnp...
#DrugDiscovery #Pharmacology #CNSDrugs #AlcoholUseDisorder
By restoring glutamate homeostasis in a reward-relevant brain region, MC-100093 highlights a target-focused, mechanism-driven strategy for AUD pharmacotherapy.
👉 Read more on: doi.org/10.1093/ijnp...
#DrugDiscovery #Pharmacology #CNSDrugs #AlcoholUseDisorder
Modulatory effects of GLT-1 enhancer, MC-100093, on glutamate uptake and associated signaling pathways in female and male alcohol preferring rats exposed to ethanol
Significance Statement This study reports the preclinical testing of novel drug, MC-100093, for the attenuation of ethanol intake. The pharmacological aspe
doi.org
January 23, 2026 at 3:09 PM
🧠 Targeting glutamate uptake pathways
By restoring glutamate homeostasis in a reward-relevant brain region, MC-100093 highlights a target-focused, mechanism-driven strategy for AUD pharmacotherapy.
👉 Read more on: doi.org/10.1093/ijnp...
#DrugDiscovery #Pharmacology #CNSDrugs #AlcoholUseDisorder
By restoring glutamate homeostasis in a reward-relevant brain region, MC-100093 highlights a target-focused, mechanism-driven strategy for AUD pharmacotherapy.
👉 Read more on: doi.org/10.1093/ijnp...
#DrugDiscovery #Pharmacology #CNSDrugs #AlcoholUseDisorder
Durability of the benefit of vagus nerve stimulation in markedly treatment-resistant major depression: a RECOVER trial report url: academic.oup.com/ijnp/article...
Durability of the benefit of vagus nerve stimulation in markedly treatment-resistant major depression: a RECOVER trial report
Significance Statement Patients with markedly treatment-resistant major depression have a low likelihood of benefiting from antidepressant treatments and a
academic.oup.com
January 16, 2026 at 6:12 PM
Durability of the benefit of vagus nerve stimulation in markedly treatment-resistant major depression: a RECOVER trial report url: academic.oup.com/ijnp/article...
Clinical Perspective: While offering clear mechanistic and safety advantages, the optimization of DORAs continues to evolve around pharmacokinetics and next-day tolerability.
Check more here: doi.org/10.1093/ijnp...
#SleepMedicine #Neuropharmacology #Insomnia #Orexin #DORA #Neurology #Psychiatry
Check more here: doi.org/10.1093/ijnp...
#SleepMedicine #Neuropharmacology #Insomnia #Orexin #DORA #Neurology #Psychiatry
Current and novel dual orexin receptor antagonists for the treatment of insomnia: the emergence of vornorexant
Abstract. Insomnia is a serious public health concern. As the widely prescribed hypnotics that positively modulate gamma-aminobutyric acid (GABA)A receptor
doi.org
January 10, 2026 at 3:38 PM
Clinical Perspective: While offering clear mechanistic and safety advantages, the optimization of DORAs continues to evolve around pharmacokinetics and next-day tolerability.
Check more here: doi.org/10.1093/ijnp...
#SleepMedicine #Neuropharmacology #Insomnia #Orexin #DORA #Neurology #Psychiatry
Check more here: doi.org/10.1093/ijnp...
#SleepMedicine #Neuropharmacology #Insomnia #Orexin #DORA #Neurology #Psychiatry
As the year draws to a close, we wish you and your loved ones a very Happy Holiday season and a peaceful, healthy, and productive New Year.
We look forward to the continued collaboration of the IJNP community in 2026.
On behalf of the IJNP Editorial Management Group
We look forward to the continued collaboration of the IJNP community in 2026.
On behalf of the IJNP Editorial Management Group
December 22, 2025 at 1:32 PM
As the year draws to a close, we wish you and your loved ones a very Happy Holiday season and a peaceful, healthy, and productive New Year.
We look forward to the continued collaboration of the IJNP community in 2026.
On behalf of the IJNP Editorial Management Group
We look forward to the continued collaboration of the IJNP community in 2026.
On behalf of the IJNP Editorial Management Group
Read more on: doi.org/10.1093/ijnp...
Individual differences in dopamine-related traits influence mood effects of dopamine D2-antagonist and antidepressant treatment expectations
AbstractBackground. High trait anhedonia and low trait extraversion have both been previously related to not only low state positive affect but also depres
doi.org
December 19, 2025 at 3:31 PM
Read more on: doi.org/10.1093/ijnp...
Dopamine's link to positive affect isn't linear—it could be U-shaped🧠
The recently published paper in IJNP shows that an individual's trait positive affectivity critically moderates how dopamine modulation influences state positive affect.
In a double-blind design:
The recently published paper in IJNP shows that an individual's trait positive affectivity critically moderates how dopamine modulation influences state positive affect.
In a double-blind design:
December 19, 2025 at 3:31 PM
Dopamine's link to positive affect isn't linear—it could be U-shaped🧠
The recently published paper in IJNP shows that an individual's trait positive affectivity critically moderates how dopamine modulation influences state positive affect.
In a double-blind design:
The recently published paper in IJNP shows that an individual's trait positive affectivity critically moderates how dopamine modulation influences state positive affect.
In a double-blind design:
Connect with the international community of neuropsychopharmacology!
Follow us across our Social Media Platforms.
linktr.ee/ijnp
Follow us across our Social Media Platforms.
linktr.ee/ijnp
November 27, 2025 at 10:48 PM
Connect with the international community of neuropsychopharmacology!
Follow us across our Social Media Platforms.
linktr.ee/ijnp
Follow us across our Social Media Platforms.
linktr.ee/ijnp
Using pooled data from three Phase 3 trials, the authors show that adjunctive brexpiprazole provides meaningful symptom relief in both minimally responsive and partially responsive patients.
Check the paper for more: doi.org/10.1093/ijnp...
Check the paper for more: doi.org/10.1093/ijnp...
November 21, 2025 at 12:26 PM
Using pooled data from three Phase 3 trials, the authors show that adjunctive brexpiprazole provides meaningful symptom relief in both minimally responsive and partially responsive patients.
Check the paper for more: doi.org/10.1093/ijnp...
Check the paper for more: doi.org/10.1093/ijnp...
Check out our new commentary in the International Journal of Neuropsychopharmacology (@ijnp.bsky.social) on ketamine–naltrexone clinical trial design for depression.
doi.org/10.1093/ijnp...
doi.org/10.1093/ijnp...
A recent commentary by @igorbandeira.bsky.social et al. highlights the steps in clinical trial design that combine ketamine and naltrexone for major depression, allowing for a mechanistic approach.
@stanfordpsy.bsky.social
#depression #opiod #ketamine #resistantdepression #clinicaltrials
@stanfordpsy.bsky.social
#depression #opiod #ketamine #resistantdepression #clinicaltrials
November 14, 2025 at 7:59 PM
Check out our new commentary in the International Journal of Neuropsychopharmacology (@ijnp.bsky.social) on ketamine–naltrexone clinical trial design for depression.
doi.org/10.1093/ijnp...
doi.org/10.1093/ijnp...
They suggest that future research should directly compare oral and depot naltrexone, systematically assess blinding, and account for comorbidities and sex differences to clarify ketamine’s mechanisms of action and guide clinical practice
Check the paper for + info: doi.org/10.1093/ijnp...
Check the paper for + info: doi.org/10.1093/ijnp...
November 14, 2025 at 7:45 PM
They suggest that future research should directly compare oral and depot naltrexone, systematically assess blinding, and account for comorbidities and sex differences to clarify ketamine’s mechanisms of action and guide clinical practice
Check the paper for + info: doi.org/10.1093/ijnp...
Check the paper for + info: doi.org/10.1093/ijnp...
💊 Distinct D₂R binding poses may produce clinically meaningful differences in efficacy, onset, and tolerability
📄 Read the full study here: doi.org/10.1093/ijnp...
📄 Read the full study here: doi.org/10.1093/ijnp...
Partial agonist antipsychotic drugs differentially interact with a secondary binding site at the dopamine D2 receptor
Highlights - Aripiprazole and brexpiprazole showed significantly increased dissociation from the dopamine D2 receptor upon L94A mutation, indicating that t
doi.org
November 7, 2025 at 12:57 PM
💊 Distinct D₂R binding poses may produce clinically meaningful differences in efficacy, onset, and tolerability
📄 Read the full study here: doi.org/10.1093/ijnp...
📄 Read the full study here: doi.org/10.1093/ijnp...
Given prolactin’s roles in mood, stress, sexual health, and bone metabolism, early endocrine assessment could inform sex-specific care in schizophrenia.
🔗 Read +: doi.org/10.1093/ijnp...
#Schizophrenia #Endocrinology #Psychiatry #FirstEpisodePsychosis #Neuroendocrinology
🔗 Read +: doi.org/10.1093/ijnp...
#Schizophrenia #Endocrinology #Psychiatry #FirstEpisodePsychosis #Neuroendocrinology
Sex-specific prolactin disturbance and divergent gonadal hormone correlates in first-episode schizophrenia
AbstractBackground. Hyperprolactinemia and altered prolactin (PRL) levels are well-documented in schizophrenia. However, very few studies have investigated
doi.org
October 27, 2025 at 1:16 PM
Given prolactin’s roles in mood, stress, sexual health, and bone metabolism, early endocrine assessment could inform sex-specific care in schizophrenia.
🔗 Read +: doi.org/10.1093/ijnp...
#Schizophrenia #Endocrinology #Psychiatry #FirstEpisodePsychosis #Neuroendocrinology
🔗 Read +: doi.org/10.1093/ijnp...
#Schizophrenia #Endocrinology #Psychiatry #FirstEpisodePsychosis #Neuroendocrinology
🧩 Read more: doi.org/10.1093/ijnp...
#Neuroscience #Microbiome #BrainHealth #Surgery #Aging #Nutraceutical
#Neuroscience #Microbiome #BrainHealth #Surgery #Aging #Nutraceutical
Mechanism of the AMPK/SIRT1 pathway in gut dysbiosis–mediated postoperative cognitive dysfunction in aged mice
AbstractObjective. Postoperative cognitive dysfunction (POCD) is a prevalent complication in older patients who undergo surgery that requires anesthesia. T
doi.org
October 24, 2025 at 1:58 PM
🧠 Brain–Body in Postoperative Cognitive Dysfunction (POCD)
POCD is a common issue in older adults after surgery, causing memory loss + slower thinking
But what if the gut has something to do with it? 🦠
IJNP paper highlights how the gut–brain axis shapes recovery after surgery.
#GutBrainAxis
POCD is a common issue in older adults after surgery, causing memory loss + slower thinking
But what if the gut has something to do with it? 🦠
IJNP paper highlights how the gut–brain axis shapes recovery after surgery.
#GutBrainAxis
October 24, 2025 at 1:58 PM
🧠 Brain–Body in Postoperative Cognitive Dysfunction (POCD)
POCD is a common issue in older adults after surgery, causing memory loss + slower thinking
But what if the gut has something to do with it? 🦠
IJNP paper highlights how the gut–brain axis shapes recovery after surgery.
#GutBrainAxis
POCD is a common issue in older adults after surgery, causing memory loss + slower thinking
But what if the gut has something to do with it? 🦠
IJNP paper highlights how the gut–brain axis shapes recovery after surgery.
#GutBrainAxis
By integrating personality dimensions into diagnostic evaluation, the study opens new perspectives for refining classification and advancing personalized treatment strategies in psychiatry.
Check the paper to find more: doi.org/10.1093/ijnp...
Check the paper to find more: doi.org/10.1093/ijnp...
Validate User
doi.org
October 10, 2025 at 11:40 AM
By integrating personality dimensions into diagnostic evaluation, the study opens new perspectives for refining classification and advancing personalized treatment strategies in psychiatry.
Check the paper to find more: doi.org/10.1093/ijnp...
Check the paper to find more: doi.org/10.1093/ijnp...
Safety and efficacy with esketamine in treatment-resistant depression: long-term extension study
doi.org/10.1093/ijnp...
doi.org/10.1093/ijnp...
Safety and efficacy with esketamine in treatment-resistant depression: long-term extension study
AbstractImportance. The rates of relapse and suicide risk are higher in treatment-resistant depression (TRD) vs non-treatment-resistant major depressive di
doi.org
October 8, 2025 at 12:51 PM
Safety and efficacy with esketamine in treatment-resistant depression: long-term extension study
doi.org/10.1093/ijnp...
doi.org/10.1093/ijnp...
This reinforces that lithium modulates unique metabolic mechanisms. However, predicting who will respond remains a complex challenge that has not yet been solved by blood metabolomics.
Read more here: doi.org/10.1093/ijnp...
#BipolarDisorder #Psychiatry #Lithium #MoodStabilizers
Read more here: doi.org/10.1093/ijnp...
#BipolarDisorder #Psychiatry #Lithium #MoodStabilizers
Identification of peripheral biomarkers through metabolomic analysis in patients with bipolar disorder treated with mood stabilizers: an exploratory study
AbstractImportance. Bipolar disorder (BD) is mainly treated with mood stabilizers, among which lithium represents the gold standard. Despite its high clini
doi.org
October 3, 2025 at 11:31 AM
This reinforces that lithium modulates unique metabolic mechanisms. However, predicting who will respond remains a complex challenge that has not yet been solved by blood metabolomics.
Read more here: doi.org/10.1093/ijnp...
#BipolarDisorder #Psychiatry #Lithium #MoodStabilizers
Read more here: doi.org/10.1093/ijnp...
#BipolarDisorder #Psychiatry #Lithium #MoodStabilizers
These findings argue for the assessment of anhedonia in clinical practice to better guide treatment management
Read+: doi.org/10.1093/ijnp...
Read+: doi.org/10.1093/ijnp...
Anhedonia is associated with a specific depression profile and poor antidepressant response
AbstractBackground. Anhedonic features within major depressive disorder (MDD) have been associated with worse course and outcome and may predict nonrespons
doi.org
September 26, 2025 at 1:50 PM
These findings argue for the assessment of anhedonia in clinical practice to better guide treatment management
Read+: doi.org/10.1093/ijnp...
Read+: doi.org/10.1093/ijnp...
New Study Alert: Anhedonia in MDD - Clinical Correlates & Treatment Response🧠
🚨New research published in IJNP confirms anhedonia (MADRS item 8 – inability to feel) as a key marker for severe MDD course.
🚨New research published in IJNP confirms anhedonia (MADRS item 8 – inability to feel) as a key marker for severe MDD course.
September 26, 2025 at 1:50 PM
New Study Alert: Anhedonia in MDD - Clinical Correlates & Treatment Response🧠
🚨New research published in IJNP confirms anhedonia (MADRS item 8 – inability to feel) as a key marker for severe MDD course.
🚨New research published in IJNP confirms anhedonia (MADRS item 8 – inability to feel) as a key marker for severe MDD course.
💡By showing how emotions and moods influence decision-making and symptom development, this paper highlights a path toward AI-driven tools that can better explain and treat psychiatric disorders
🔗Read the Editor’s Pick doi.org/10.1093/ijnp...
#ComputationalPsychiatry #MentalHealth #DigitalPsychiatry
🔗Read the Editor’s Pick doi.org/10.1093/ijnp...
#ComputationalPsychiatry #MentalHealth #DigitalPsychiatry
The role of affective states in computational psychiatry
Abstract. Studying psychiatric illness has often been limited by difficulties in connecting symptoms and behavior to neurobiology. Computational psychiatry
doi.org
September 19, 2025 at 6:32 PM
💡By showing how emotions and moods influence decision-making and symptom development, this paper highlights a path toward AI-driven tools that can better explain and treat psychiatric disorders
🔗Read the Editor’s Pick doi.org/10.1093/ijnp...
#ComputationalPsychiatry #MentalHealth #DigitalPsychiatry
🔗Read the Editor’s Pick doi.org/10.1093/ijnp...
#ComputationalPsychiatry #MentalHealth #DigitalPsychiatry
Read more: doi.org/10.1093/ijnp...
#AlcoholUseDisorder #Hippocampus #Neurogenesis #AddictionResearch
#AlcoholUseDisorder #Hippocampus #Neurogenesis #AddictionResearch
Validate User
doi.org
September 5, 2025 at 1:09 PM
Just noticed a couple of new-ish papers from the neuro-psychopharmacology team at UoA. First, qualitative interviews with participants in the open-label trial that preceded the current trial of LSD microdosing for major depressive disorder: academic.oup.com/ijnp/article...
September 4, 2025 at 10:01 PM
Just noticed a couple of new-ish papers from the neuro-psychopharmacology team at UoA. First, qualitative interviews with participants in the open-label trial that preceded the current trial of LSD microdosing for major depressive disorder: academic.oup.com/ijnp/article...
Check the paper to see how it uncovered insights into: doi.org/10.1093/ijnp...
✨How mitochondria adapt to stress
🔄The regulatory landscape governing mitochondrial function & cellular resilience
🌀Biological pathways relevant to stress-related disorders
✨How mitochondria adapt to stress
🔄The regulatory landscape governing mitochondrial function & cellular resilience
🌀Biological pathways relevant to stress-related disorders
Stress-Induced Altered Expression of Hippocampal Nuclear and Mitochondrial Encoded Genes in Rats and Cross-Species Genetic Associations Reveal Molecular Links to Depression
AbstractBackground. Mitochondria play a pivotal role in energy production, and their dysfunction not only hampers cells' ability to meet energy requirement
doi.org
August 29, 2025 at 10:53 AM
Check the paper to see how it uncovered insights into: doi.org/10.1093/ijnp...
✨How mitochondria adapt to stress
🔄The regulatory landscape governing mitochondrial function & cellular resilience
🌀Biological pathways relevant to stress-related disorders
✨How mitochondria adapt to stress
🔄The regulatory landscape governing mitochondrial function & cellular resilience
🌀Biological pathways relevant to stress-related disorders
We are delighted to announce that the abstracts from CINP-AsCNP 2025 Joint Congress in Melbourne have been published as a Supplement to the International Journal of Neuropsychopharmacology
Read the abstracts here:
academic.oup.com/ijnp/issue/2...
Read the abstracts here:
academic.oup.com/ijnp/issue/2...
Volume 28 Issue Supplement_2 | International Journal of Neuropsychopharmacology | Oxford Academic
The official journal of Collegium Internationale Neuro-Psychopharmacologicum. Publishes papers that advance understanding of existing and new neuropsychopharmacological agents or provide insights into...
academic.oup.com
August 29, 2025 at 10:06 AM
We are delighted to announce that the abstracts from CINP-AsCNP 2025 Joint Congress in Melbourne have been published as a Supplement to the International Journal of Neuropsychopharmacology
Read the abstracts here:
academic.oup.com/ijnp/issue/2...
Read the abstracts here:
academic.oup.com/ijnp/issue/2...